12.20.24 -- Leading Through Biotech's Perfect Storm: Lessons From The Front Lines

This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On the Business of Biotech, Vik Bajaj, Managing Director at Foresite Capital and Cofounder and CEO at Foresite Labs, takes us behind the scenes, and shares his worldview on the role of advanced computing technology in drug development.

Explore several actionable strategies to help ensure medical advancements benefit all populations through diverse representation in clinical trials.

Adaptability is crucial for developers as they upscale the production of viral vectors. Discover the benefits of using suspension cell lines and why adherent cell culture shouldn’t be left behind.

Transitioning from R&D to clinical trials is challenging, but incorporating automation can be a big step toward overcoming technology challenges, streamlining operations, and reducing error rates.

The pharma industry is identifying ways to make processes more sustainable. Learn how nanoparticle engineering technology can both empower sustainability goals and lead to better patient outcomes.

Developing targeted therapies is a complex journey, requiring a deep understanding of disease, innovative approaches, and close collaboration with experts.